Cargando…
Oral vaccination with novel Lactococcus lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella abortus
This work aimed to provide recombinant Lactococcus lactis as a potential live vector for the manufacture of recombinant Brucella abortus (rBLS-Usp45). The sequences of the genes were collected from the GenBank database. Using Vaxijen and ccSOL, the proteins' immunogenicity and solubility were e...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025791/ https://www.ncbi.nlm.nih.gov/pubmed/36939918 http://dx.doi.org/10.1007/s00203-023-03471-6 |
_version_ | 1784909413785534464 |
---|---|
author | Fatehi, Zahra Doosti, Abbas Jami, Mohammad Saeid |
author_facet | Fatehi, Zahra Doosti, Abbas Jami, Mohammad Saeid |
author_sort | Fatehi, Zahra |
collection | PubMed |
description | This work aimed to provide recombinant Lactococcus lactis as a potential live vector for the manufacture of recombinant Brucella abortus (rBLS-Usp45). The sequences of the genes were collected from the GenBank database. Using Vaxijen and ccSOL, the proteins' immunogenicity and solubility were evaluated. Mice were given oral vaccinations with recombinant L. lactis. Anti-BLS-specific IgG antibodies were measured by ELISA assay. Cytokine reactions were examined using real-time PCR and the ELISA technique. The BLS protein was chosen for immunogenicity based on the vaccinology screening findings since it had maximum solubility and antigenic values of 99% and 0.75, respectively. The BLS gene, digested at 477 bp, was electrophoretically isolated to demonstrate that the recombinant plasmid was successfully produced. Protein-level antigen expression showed that the target group produced the 18 kDa-sized BLS protein, whereas the control group did not express any proteins. In the sera of mice given the L. lactis-pNZ8148-BLS-Usp45 vaccine 14 days after priming, there was a significant level of BLS-specific IgG1, IgG2a (P < 0.001) compared to the PBS control group. Vaccinated mice showed higher levels of IFN-γ, TNFα, IL-4, and IL-10 in samples obtained on days 14 and 28, after receiving the L. lactis-pNZ8148-BLS-Usp45 and IRBA vaccines (P < 0.001). The inflammatory reaction caused less severe spleen injuries, alveolar edema, lymphocyte infiltration, and morphological damage in the target group's spleen sections. Based on our findings, an oral or subunit-based vaccine against brucellosis might be developed using L. lactis-pNZ8148-BLS-Usp45 as a novel, promising, and safe alternative to the live attenuated vaccines now available. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00203-023-03471-6. |
format | Online Article Text |
id | pubmed-10025791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-100257912023-03-21 Oral vaccination with novel Lactococcus lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella abortus Fatehi, Zahra Doosti, Abbas Jami, Mohammad Saeid Arch Microbiol Original Paper This work aimed to provide recombinant Lactococcus lactis as a potential live vector for the manufacture of recombinant Brucella abortus (rBLS-Usp45). The sequences of the genes were collected from the GenBank database. Using Vaxijen and ccSOL, the proteins' immunogenicity and solubility were evaluated. Mice were given oral vaccinations with recombinant L. lactis. Anti-BLS-specific IgG antibodies were measured by ELISA assay. Cytokine reactions were examined using real-time PCR and the ELISA technique. The BLS protein was chosen for immunogenicity based on the vaccinology screening findings since it had maximum solubility and antigenic values of 99% and 0.75, respectively. The BLS gene, digested at 477 bp, was electrophoretically isolated to demonstrate that the recombinant plasmid was successfully produced. Protein-level antigen expression showed that the target group produced the 18 kDa-sized BLS protein, whereas the control group did not express any proteins. In the sera of mice given the L. lactis-pNZ8148-BLS-Usp45 vaccine 14 days after priming, there was a significant level of BLS-specific IgG1, IgG2a (P < 0.001) compared to the PBS control group. Vaccinated mice showed higher levels of IFN-γ, TNFα, IL-4, and IL-10 in samples obtained on days 14 and 28, after receiving the L. lactis-pNZ8148-BLS-Usp45 and IRBA vaccines (P < 0.001). The inflammatory reaction caused less severe spleen injuries, alveolar edema, lymphocyte infiltration, and morphological damage in the target group's spleen sections. Based on our findings, an oral or subunit-based vaccine against brucellosis might be developed using L. lactis-pNZ8148-BLS-Usp45 as a novel, promising, and safe alternative to the live attenuated vaccines now available. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00203-023-03471-6. Springer Berlin Heidelberg 2023-03-20 2023 /pmc/articles/PMC10025791/ /pubmed/36939918 http://dx.doi.org/10.1007/s00203-023-03471-6 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Paper Fatehi, Zahra Doosti, Abbas Jami, Mohammad Saeid Oral vaccination with novel Lactococcus lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella abortus |
title | Oral vaccination with novel Lactococcus
lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella
abortus |
title_full | Oral vaccination with novel Lactococcus
lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella
abortus |
title_fullStr | Oral vaccination with novel Lactococcus
lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella
abortus |
title_full_unstemmed | Oral vaccination with novel Lactococcus
lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella
abortus |
title_short | Oral vaccination with novel Lactococcus
lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella
abortus |
title_sort | oral vaccination with novel lactococcus
lactis mucosal live vector-secreting brucella lumazine synthase (bls) protein induces humoral and cellular immune protection against brucella
abortus |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025791/ https://www.ncbi.nlm.nih.gov/pubmed/36939918 http://dx.doi.org/10.1007/s00203-023-03471-6 |
work_keys_str_mv | AT fatehizahra oralvaccinationwithnovellactococcuslactismucosallivevectorsecretingbrucellalumazinesynthaseblsproteininduceshumoralandcellularimmuneprotectionagainstbrucellaabortus AT doostiabbas oralvaccinationwithnovellactococcuslactismucosallivevectorsecretingbrucellalumazinesynthaseblsproteininduceshumoralandcellularimmuneprotectionagainstbrucellaabortus AT jamimohammadsaeid oralvaccinationwithnovellactococcuslactismucosallivevectorsecretingbrucellalumazinesynthaseblsproteininduceshumoralandcellularimmuneprotectionagainstbrucellaabortus |